Monday, March 4, 2024

March 04, 2024 at 11:09PM Kedbumin

Product approval information is indicated for:
o Hypovolemic shock
o Hypoalbuminemia
o Prevention of central volume depletion after paracentesis due to cirrhotic ascites
o Ovarian Hyperstimulation Syndrome (OHSS)
o Adult Respiratory Distress Syndrome (ARDS)
o Burns
o Hemodialysis patients undergoin

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/tL4Qv10

No comments:

Post a Comment